1441
CART-38 in Adult AML and MM Patients
Condition(s):Acute Myeloid Leukemia (AML); Multiple Myeloma (MM)Last Updated:October 14, 2022Not yet recruiting
Refractory Multiple Myeloma: 1455 Clinical Trials, Page 145 of 146
Hide Studies Not Open or Pending
1442
Lenalidomide in HTLV-1 Adult T-Cell Leukemia
Condition(s):Adult T Cell Leukemia/LymphomaLast Updated:May 23, 2016Completed
1443
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Condition(s):Amyloid; AL Amyloidosis; Refractory AL AmyloidosisLast Updated:June 9, 2022Recruiting
1444
Lenalidomide Plus Chemotherapy for AML
Condition(s):Acute Myelogenous LeukemiaLast Updated:March 17, 2016Completed
1445
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Condition(s):Non Hodgkin Lymphoma; Richter Transformation; Multiple Myeloma; T-cell-prolymphocytic Leukemia; Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Myeodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myelofibrosis; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Chronic Myelomonocytic Leukemia-2; Myelodysplastic Neoplasm in Blast PhaseLast Updated:October 12, 2022Recruiting
1446
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib
Condition(s):Acute Myeloid LeukemiaLast Updated:March 27, 2023Completed
1447
Multi Cohort Study of Tazemetostat in Combination With Various Treatments For R/R Hematologic Malignancies
Condition(s):Relapsed/RefractoryLast Updated:October 24, 2022Recruiting
1448
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
Condition(s):Multiple MyelomaLast Updated:July 22, 2020Completed
1449
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression
Condition(s):Multiple MyelomaLast Updated:August 18, 2021Recruiting
1450
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Condition(s):Multiple Myeloma; Blood and Marrow Transplant (BMT)Last Updated:December 17, 2012Unknown status